Trial Profile
Phase Ib trial of PRI 724 combination therapy in patients with solid tumours.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2013
Price :
$35
*
At a glance
- Drugs Foscenvivint (Primary) ; Antineoplastics
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors PRISM Pharma Co
- 14 Feb 2013 New trial record